Loading
A phase 2/3 trial of Serplulimab, Bevacizumab in colorectal cancer, run by Shanghai Henlius Biotech, now recruiting.
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) is a phase 2/3 interventional study registered as NCT04547166 by Shanghai Henlius Biotech, with 568 participants planned, started 2021-03-10 and due to reach its primary completion in 2025-09-24. Interventions recorded: HLX10, HLX04、. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Shares Shanghai Henlius Biotech, Serplulimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/